1 / 48

Valvular Heart Disease

Valvular Heart Disease. Jay L. Rubenstone, D.O., F.A.C.C. Fall 2012. Normal Structure Mitral Valve. Cross sectional Area 4-6cm2 Anterior and Posterior Leaflets Chordae Tendineae  Papillary Muscles. Mitral Stenosis Etiology & Pathology. Rheumatic Fever- 99% Other Congenital

daktari
Download Presentation

Valvular Heart Disease

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Valvular Heart Disease Jay L. Rubenstone, D.O., F.A.C.C Fall 2012

  2. Normal StructureMitral Valve • Cross sectional Area 4-6cm2 • Anterior and Posterior Leaflets • Chordae Tendineae  Papillary Muscles

  3. Mitral StenosisEtiology & Pathology • Rheumatic Fever- 99% • Other • Congenital • Carcinoid • Lupus • Amyloid • Infective Endocarditis • Mucopolysaccharide Disease

  4. Pathophysiology • Mild MS- orifice <2 cm2 • Critical MS- <1 cm2 • A-V pressure gradient >20mmHg • Increased LA Pressure • Increase Pulmonary Venous + Capillary Pressures • Increase Pulmonary Artery Systolic Pressure • Decrease RV Function (when PAS>30-60mmHg)

  5. Pathophysiology • Pulmonary HTN • Passive Backward Transmission Of Incr. LA pressure Pulmonary Arteriolar Constriction Organic Obliterative Changes in Pulmonary Vascular Bed RV Failure

  6. History • Exertional Dyspnea • Cough/Wheezing • Orthopnea/PND/CHF • Hemoptysis-Rupture of Pulm Vein-Brochial Vein Shunts

  7. History • Chest Pain-Increase RV Pressures or Unknown Etiology • Systemic Emboli (LA clots) • Increased LA size, Decreased C.O., Atrial Fib, IE • Significantly decreased w/anticoagulation

  8. Diagnosis • Cardiac Catherization • Gorlin Equation

  9. Natural History • Asymptomatic for 15-20yrs following Rheumatic Fever • Additional 5-10 yrs for progression from mild to severe stenosis • Stenosis progression approx. .09 cm2/yr

  10. Natural History • Presurgical Survival Rates • NYHA Class II 80%-10yrs • Class III 38%-10yrs, 62% 5yrs • Class IV 15%-5yrs

  11. Management-Medical • Endocarditis Prophylaxis • Activity Limitation • Diruetics- Decrease Na Intake • Heart Rate Control for A-fib or Sinus Rhythm • Anticoagulation

  12. Percutaneous Balloon Angioplasty • Moderate-Severe MS • Mild MS- if Pulmonary Artery Pressures or Wedge Pressure Elevate with Exercise

  13. Valve Replacement • Indications • Combined MS/MR • <1.5 cm2-NYHA III or IV • <1 cm2 • Class II if Pulm Artery Pressure >70mmHg • Mortality • 3-8% • Valve Type-Prosthetic or Bioprosthetic, TAVR

  14. Mitral Regurgitation • Etiology • Rheumatic Heart Disease • Infective Endocarditis • Collagen Vascular Disease • Cardiomyopathy • Ischemic Heart Disease • Mitral Valve Prolapse-most common cause for valve surgery in US

  15. Pathophysiology • Decreased Impedance to Ventricular Emptying • Determinants of Regurgitant Flow • Instantaneous Size of MV Orifice • Dependent on Preload, Afterload, LV Contractility, LV Size • LA-LV Pressure Gradient dependent on Systemic Vascular Resistance, LV Pressure, & LV Size

  16. Pathophysiology • LV Compensation • Increased End Diastolic Volume • Increased Wall Tension • Increased Preload • Increased LV Emptying • Normal Ejection Fraction should be Super Normal >65% to maintain forward cardiac output and B/P

  17. Pathophysiology • LV Decompensation • Increase End Systolic Volume • Increased End Diastolic Volume • Leads to Annulus Dilatation (MR begets MR) • Decreased Ejection Fraction and Stroke Volume

  18. Pathophysiology • Ejection Fraction in Mitral Regurgitation • >65% normal in compensated MR • 50-65% mild impairment • 40-50% moderate-severe impairment • <35% advanced impairment As ejection fraction decreases operative risk increases.

  19. History • Shortness of Breath • Exertional Dyspnea • Congestive Heart Failure • RHF • Significant symptoms in chronic MR usually do not develop until LV decompensation occurs.

  20. History • Medical Treatment Survival • 80% 5yr • 60% 10yr • 30-45% 5yr if MR severe

  21. Management of Chronic MR • Medical • Digoxin • Diruetics* • Afterload Reduction • Anticoagulation in A-fib • Endocarditis Prophylaxis

  22. Management of Chronic MR • Surgical • Indications • Asymptomatic Class I • EF < 60% or LV Systolic Diameter >45mm • Severe MR Class II, III, or IV • generally considered for surgery unless EF <30% • Valve Repair vs. Replacement

  23. Mitral Valve Prolapse • Systolic Click-Murmur Syndrome • Barlow’s Syndrome • Billowing Mitral Valve Syndrome • Floppy Valve Syndrome • Myxomatous Valve Syndrome • Parachute Valve

  24. Mitral Valve Prolapse • Over diagnosed • 2.4% of population • Females>Males 2:1 • Severe MR- Elderly Male>Young Female

  25. MVP Etiology • Primary Valvular most frequent • Connective Tissue Diseases • Hyperthyroidism • Myotonic Dystrophy • Periarteritis Nodosa • Von Willebrands

  26. MVP Pathology • Myxomatous Proliferation and Degeneration of Valve Leaflets • Increased Quantity of Acid Mucopolysaccharide in Middle Layer of Valve Tissue

  27. MVP History • Most are asymptomatic throughout life • Chest pain, fatigue, anxiety • Orthostasis-questionable autonomic dysfunction • Arrhythmia-SVT, PACs, PVCs • Symptoms of MR if present

  28. Physical Examination • Ascultation • Murmur- mid to late crescendo progressing to holosystolic if MR becomes severe • Click and murmur move closer to S1 during strain phase of valsalva, sudden standing, and Amyl Nitrate

  29. Natural History • Progressive MR in 15% over 10-15 yrs • Infective Endocarditis • Cerebral Emboli-tearing of endothelial covering of myxomatous valve with platelet activation • Sudden Cardiac Death-V fib, increased Q-T interval (not well established)

  30. MVP Management • Endocarditis prophylaxis if MR present • Holter monitor-beta blocker for ectopy? • Aspirin if focal neurological events present • MR-treat like any other MR, valves usually amenable to repair • *MVP is usually a benign disease*

  31. Aortic ValveNormal Structure • Valve sits at the base of Aortic Root • Three Leaflets (cusps)-non coronary, right coronary, left coronary • Cusps give rise to ostea of right coronary artery and left main coronary artery • Normal cross-sectional area 3-4cm2

  32. Aortic Stenosis Etiology and Pathology • Valvular • Supravalvular • Subvalvular • Hyperthrophic Cardiomyopathy

  33. Congenital Aortic Stenosis • Unicuspid • Presents less than one year of age • Bicuspid • Adult Presentation • Chronic turbulent flow • Leads to fibrosis, rigidity, calcification • Tricuspid • Leaflets of unequal size

  34. Acquired Aortic Stenosis • Rheumatic • Rare • Usually mitral valve also involved • Degenerative or Senile • Most common cause of adult AS • Most common cause of valve replacement • Years of normal mechanical stress leads to calcium deposits on leaflets • Inflammatory or Infectious component?? • >age 65 2% frank AS, 30% Aortic Sclerosis

  35. Hemodynamics • Severe AS • Mean systolic pressure gradient ≥ 40mmHg in the presence of normal cardiac output • Valve area ≤ 1.0cm2 • Moderate AS • 1-1.5cm2 • Mild AS • 1.5-2cm2 • Aortic Sclerosis

  36. History • Long latent period of increasing obstruction • Symptoms usually begin in 5th or 6th decade • Angina in 2/3 of patients • Hyperthrophied myocardium • Increased ventricular systolic pressure • All of which increase myocardial oxygen consumption • Oxygen supply-demand imbalance leads to subendocardial ischemia

  37. History • Syncopy • Reduced cerebral perfusion • Vasodilation in the presence of fixed cardiac output leads to hypotension • Baroreceptor-vasodepression due to high LV systolic pressure • Dyspnea (CHF) • Particularly with exertion due to fixed cardiac output • Pulmonary Venous HTN can lead to CHF

  38. Natural History • Asymptomatic latent period • With moderate-severe AS valve area can decrease on average 0.12cm2 per year • *Angina, synocopy or CHF • Average 1-3 year survival 50% • Sudden cardiac death rare

  39. Surgery (Valve Replacement) • Indications • Symptomatic Patients -valve area ≤ 1.0cm2 Asymptomatic Patients-progressive LV disfunction (EF <35%) or hypotensive response to mild exercise • Delaying surgery in asymptomatic patients with good exercise tolerance is controversial • Valve type Prosthetic, Bioprosthetic or TAVR

  40. KEEPSurgery (Valve Replacement) • Results • Effective prosthetic valve area not normal • Surgery replaces Critical AS with Non-critical AS • Symptoms can persist if valve-patient mismatch occurs • 10 year survival –85%

  41. Aortic RegurgitationEtiology and Pathology • Valvular • Rheumatic-Fibrotic Retraction of Leaflets • Ankylosing Spondylitis, Behcets, Psoratic Arthritis, Giant Cell Arteritis • Degenerative AS-75% w/AR • Infective Endocarditis-Leaflet Distruction • Trauma-ascending aortic tear • Bicuspid aortic valve-prolapse or incomplete closure • Myxomatous Degeneration-like MVP • Appetite suppressant drugs-serotonin related valve deposits

  42. Etiology and Pathology • Aortic Root Disease-More common than primary valvular. Root Dilatation leads to non-coaptation of leaflets. • Degenerative-Hypertensive Aortic Dilatation • Cystic Medial Necrosis-Classic Marfans Syndrome • Aortic Dissection • Syphilitic Aortitis • Rheumatic Disease-same as valvular

  43. History • Acute AR • LV cannot accommodate acute regurgitant volume • can lead to cardiovascular collapse • Chronic AR • Gradual LV enlargement-eccentric hypertrophy • Exertional dyspnea, orthopnea, PND, CHF • Presents 4th or 5th Decade

  44. Natural History • Acute AR • Cardiovascular collapse • Inotrophic agents and vasodilators • Prompt surgical intervention • Chronic AR • 75% Five Year Survival • 50% Ten Year Survival • Progressive downhill course of CHF, Episodic Pulmonary Edema, Sudden Cardiac Death

  45. Medical Treatment • Acute AR • As above • Chronic AR • Asymptomatic Mild-Moderate • Follow by Echo Yearly • Endocarditis Prophalaxis for all AR • May not require medical treatment

  46. Medical Treatment • Symptomatic Moderate-Severe AR • Limit exertional activity • Aggressively treat B/P • Diuretics • Salt Restriction • Digoxin • Vasodilators (Nifedipine?)

  47. Surgical Treatment • Indications • Defer surgery for chronic severe AR if good exercise tolerance, EF greater than 50%, end systolic diameter < 50 mm, and end diastolic diameter < 70 mm • Be aware that progressive decline in LV function or size increases surgical morbidity and mortality

  48. Surgical Treatment • Mortality • 3-8% perioperative • 5-10% late mortality with significant preop LV dysfunction

More Related